Moreover, a close relationship between IDO2 expression, increased PD-L1 levels, tumor-infiltrating lymphocytes localization, and NSCLC poor prognosis was detected, making it possible for IDO2 to be a potential prognostic biomarker or part of combined therapies with immune checkpoint inhibitors. Here, IDO2 is linked to neoplasm.